Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
151.8 USD | +11.63% | -0.73% | 0.00% |
09:57am | Kenvue Prices Secondary Common Stock Offering | MT |
14/05 | Transcript : Johnson & Johnson Presents at Bank of America Health Care Conference 2024, May-14-2024 01:40 PM |
Sales 2024 * | 88.37B 7,375B | Sales 2025 * | 90.78B 7,576B | Capitalization | 364B 30,403B |
---|---|---|---|---|---|
Net income 2024 * | 22.04B 1,839B | Net income 2025 * | 23.09B 1,927B | EV / Sales 2024 * | 4.04 x |
Net cash position 2024 * | 7B 584B | Net cash position 2025 * | 21.07B 1,759B | EV / Sales 2025 * | 3.78 x |
P/E ratio 2024 * |
16.8
x | P/E ratio 2025 * |
15.9
x | Employees | - |
Yield 2024 * |
3.19% | Yield 2025 * |
3.33% | Free-Float | 77.08% |
Latest transcript on Johnson & Johnson
1 week | -0.73% | ||
3 months | -22.29% |
Managers | Title | Age | Since |
---|---|---|---|
Joaquin Duato
CEO | Chief Executive Officer | 61 | 01/89/01 |
Joseph Wolk
DFI | Director of Finance/CFO | 57 | 01/98/01 |
James Swanson
CTO | Chief Tech/Sci/R&D Officer | 58 | 05/19/05 |
Members of the board | Title | Age | Since |
---|---|---|---|
Marillyn Hewson
BRD | Director/Board Member | 70 | 25/19/25 |
D. Davis
BRD | Director/Board Member | 72 | 19/14/19 |
Anne Mulcahy
BRD | Director/Board Member | 70 | 22/09/22 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+30.70% | 588B | |
+18.02% | 326B | |
+4.27% | 285B | |
+14.75% | 239B | |
+9.80% | 210B | |
-7.81% | 200B | |
+8.12% | 167B | |
-1.42% | 161B | |
+1.52% | 124B |
- Stock Market
- Equities
- JNJ Stock
- JNJ Stock